跳至主要内容
临床试验/EUCTR2009-014770-17-NL
EUCTR2009-014770-17-NL进行中(未招募)1 期

ew influenza A (H1N1) disease incidence and immunogenicity of the pandemic influenza A (H1N1) vaccine in healthy adults

etherlands Vaccine Institute0 个研究点目标入组 375 人开始时间: 2009年10月23日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
375

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Subjects have to fulfill all of the following criteria:
  • - age 18 – 52 years
  • - good self-reported health according to the investigator
  • - willingness and ability to adhere to the study regimen
  • - having a signed informed consent (IC) form
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • The contra-indications for receiving the pandemic influenza vaccine are exclusion criteria: allergy to any of the components of the vaccine or trace residues of eggs, chicken proteins, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB).
  • The exclusion criteria for blood collection and the immunological analysis are:
  • - immune deficiencies
  • - haematological disorders
  • - bleeding disorders
  • - usage of anticoagulants, corticosteroids, NSAIDs and/or statins
  • - diabetes mellitus
  • - having had an infectious disease with fever within the last two weeks
  • - previously diagnosed with pandemic H1N1 influenza

研究者

发起方
etherlands Vaccine Institute

相似试验